Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹5 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹-1 Cr
ROE
-34.9 %
ROCE
-9.1 %
P/E Ratio
--
P/B Ratio
4.9
Industry P/E
39.17
EV/EBITDA
-17.7
Div. Yield
0 %
Debt to Equity
0
Book Value
₹--
EPS
₹-0.5
Face value
10
Shares outstanding
19,111,400
CFO
₹-3.22 Cr
EBITDA
₹-15.03 Cr
Net Profit
₹-18.97 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Advik Pharmaa
| -34.7 | 4.6 | -21.7 | -21.2 | 20.0 | -- | -5.6 |
|
BSE Healthcare*
| -4.6 | 0.9 | 5.1 | 17.0 | 27.1 | 21.6 | 10.3 |
|
BSE Small Cap#
| -4.4 | 1.8 | 13.8 | 1.9 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2019
|
2018
|
|---|---|---|---|
|
Advik Pharmaa
| 50.9 | -83.2 | -61.3 |
|
BSE Small Cap
| 29.0 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Advik Pharmaa
|
2.8 | 5.3 | 0.0 | -0.9 | -- | -68.9 | -- | 4.9 |
| 440.7 | 4,025.9 | 2,387.0 | 168.1 | 9.7 | 12.7 | 23.9 | 2.9 | |
| 998.2 | 12,264.1 | 2,386.9 | 485.6 | 26.1 | 18.1 | 25.3 | 4.4 | |
| 321.0 | 3,498.3 | 150.8 | 48.8 | 42.1 | 20.7 | 71.7 | 14.1 | |
| 285.1 | 2,624.5 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.6 | |
| 61.5 | 3,369.9 | 1,811.6 | 118.0 | 8.0 | 10.4 | 28.6 | 2.9 | |
| 689.8 | 3,504.9 | 921.9 | 95.8 | 9.0 | 8 | 35.2 | 2.8 | |
| 2,381.7 | 3,944.5 | 653.4 | 183.2 | 21.2 | 20.9 | 21.5 | 7.4 | |
| 227.3 | 4,949.2 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 45.0 | |
| 586.4 | 4,130.0 | 2,028.9 | 150.6 | 7.5 | 6.2 | 30 | 1.7 |
No Review & Analysis are available.
Advik Laboratories Limited manufactures, markets, trades, and exports pharmaceutical products. It offers generic products, such as antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis,... corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products; and ethical products. The company markets and sells its products in India, the Middle East, South America, and Africa. Advik Laboratories Limited was founded in 1994 and is based in New Delhi, India. Read more
Incorporated
1994
Chairman
--
Managing Director
Peeyush Kumar Aggarwal
Headquarters
Mewat Dist, Haryana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Advik Laboratories Ltd stood at ₹ 9 Cr as on 31-Mar-25
The share price of Advik Laboratories Ltd is ₹2.75 (BSE) as of 16-Jun-2025 IST. Advik Laboratories Ltd has given a return of 20.04% in the last 3 years.
Advik Laboratories Ltd has a market capitalisation of ₹ 5 Cr as on 16-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Advik Laboratories Ltd is 4.91 times as on 16-Jun-2025, a 54% premium to its peers’ median range of 3.18 times.
Since, TTM earnings of Advik Laboratories Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Advik Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Advik Laboratories Ltd.
Advik Laboratories Limited manufactures, markets, trades, and exports pharmaceutical products. It offers generic products, such as antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis, corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products; and ethical products. The company markets and sells its products in India, the Middle East, South America, and Africa. Advik Laboratories Limited was founded in 1994 and is based in New Delhi, India.
The promoters of Advik Laboratories Ltd are OMKAM PHARMACEUTICALS PRIVATE LIMITED and PEEYUSH KUMAR AGGARWAL. They collectively own 35.89 per cent of the total equity. The chairman of the company is
The promoters of Advik Laboratories Ltd have pledged 5.76% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
12,264
|
|
|
4,949
|
|
|
4,130
|
|
|
4,026
|
|
|
3,944
|
|
|
3,505
|
|
|
3,498
|
|
|
3,370
|
|
|
2,624
|
| Advik Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-68.92
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-1872.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Advik Laboratories Ltd was ₹-1 Cr.
₹-0.01
(
